Inferra AIResearch Tools

Inferra AI / Company / VERA

Vera Therapeutics, Inc.

VERA · Health Care

Last earnings Aug 10, 2026

AI analysis

Q2 2025 · reported Aug 5, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

No extracted figures held

The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Vera reported $556.8 million in cash, cash equivalents, and marketable securities as of June 30, 2025, which combined with its undrawn debt facility, Vera believes to be sufficient to fund operations through potential approval and U.

If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results • On track to submit a Biologics License Application (BLA) for accelerated approval of atacicept to U.S

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

Vera reported $556.8 million in cash, cash equivalents, and marketable securities as of June 30, 2025, which combined with its undrawn debt facility, Vera believes to be sufficient to fund operations through potential approval and U.

SEC original ↗Vera Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.

SEC original ↗Vera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026

If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.

SEC original ↗Vera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026

The Company has funded its operations primarily through the issuance of common stock, redeemable convertible preferred stock, debt financing and convertible notes.

SEC original ↗Vera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Management believes that the Company s cash, cash equivalents and marketable securities as of June 30, 2026 will be sufficient to fund its planned operations and capital expenditure requirements for at least the next 12 months subsequent to the issuance date of these financial statements.

SEC original ↗Vera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026

The Company intends to raise additional capital through public or private equity offerings, debt financing, or other capital sources, which may include strategic collaborations or other arrangements with third parties in order to achieve its long-term business objectives.

SEC original ↗Vera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Strategy & priorities

(Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the second quarter ended June 30, 2025.

SEC original ↗Vera Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

About Vera Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases.

SEC original ↗Vera Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.

SEC original ↗Vera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026

(the Company) is a commercial-stage biotechnology company focused on developing and commercializing treatments for patients with serious immunological diseases.

SEC original ↗Vera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026

The Company operates in one segment, Therapeutics, focused on developing and commercializing transformative treatments for patients with serious immunological diseases.

SEC original ↗Vera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Risks & headwinds

Because such statements are subject to risk and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.

SEC original ↗Vera Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera’s business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera’s filings with the U.

SEC original ↗Vera Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Legal Proceedings 28 Item 1A.

SEC original ↗Vera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026

2 Unfavorable geopolitical and global economic conditions, including tariffs and trade tensions, could adversely affect our business, financial condition and results of operations.

SEC original ↗Vera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026

If we experience material weaknesses in internal control over financial reporting in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock.

SEC original ↗Vera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026

We may be subject to securities litigation, which is expensive and could divert management attention.

SEC original ↗Vera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

30 documents

Earnings releases

9 documents

Presentations

0 documents

No presentations for Vera Therapeutics, Inc. are held in this edition of the library.

Transcripts

0 documents

No transcripts for Vera Therapeutics, Inc. are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.